Pharmaceutical Industry Shaken By Policy Shifts and Strategic Deals

Recent developments in the pharmaceutical industry reveal drugmakers delaying European launches due to US pricing pressures, strategic acquisitions like Eli Lilly's Centessa buyout, and FDA concerns over potential liver injuries from Amgen drugs. Meanwhile, technological advances like Butterfly's AI ultrasound tool and regulatory changes shape the healthcare landscape.

Pharmaceutical companies are re-evaluating their strategies amid ongoing US policy shifts. Drugmakers are hesitating to launch some new medications in Europe, largely due to the implications of pricing policies under former President Trump's administration. These policies sought to tie US drug prices to those in Europe, where medication costs are typically lower.

Additionally, major players like Eli Lilly are diversifying their portfolios. Lilly has announced a $7.8 billion acquisition of Centessa Pharmaceuticals, aiming to expand into the sleep disorder treatment sector. Centessa's innovative therapies could provide new approaches to managing sleep-related ailments.

Furthermore, technology and regulations are at the forefront with the FDA identifying liver injury risks in patients using Amgen's drugs. Meanwhile, Butterfly Network has introduced an AI-driven ultrasound tool to estimate gestational age, heralding increased accessibility to maternal care. These developments highlight the dynamic shifts within the healthcare industry.

(With inputs from agencies.)